BioVentrix today said it appointed Jim Dillion as president and CEO.
Prior to joining the company, Dillion was the cofounder of Reprieve Cardiovascular and led its financing and development of a therapy for acute decompensated heart failure. He has also held a number of leadership roles at St. Jude Medical, Abiomed, TherOx and InfraReDx.
“Jim’s field-based leadership style, combined with his proven success in building high-performance global teams, makes him the ideal candidate to lead our company,” board chairperson Steven Healy said in a news release. “Jim’s knowledge and experience in market development, ability to ensure a business’s financial integrity and his strong relationships with renowned physicians will prove highly beneficial in building BioVentrix and optimizing shareholder value. I would also like to thank Ken Miller for his years of service and many contributions to BioVentrix.”
“I am excited to join the BioVentrix team at a pivotal time in the company’s growth,” Dillon said. “This is a unique chance to revolutionize the treatment of congestive heart failure caused by ischemic cardiomyopathy and provide a better quality of life for countless patients worldwide.”